Navigation Links
Second-line CML drugs evoke faster response than front-line therapy
Date:12/7/2009

NEW ORLEANS ― Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

Initial therapy for CML remains imatinib, a Novartis drug known as Gleevec, which has increased the five-year survival rate for the disease from 50 percent to 90 percent of patients. In separate clinical trials, M. D. Anderson researchers are comparing nilotinib, a Novartis drug known as Tasigna, and dasatinib, a Bristol-Myers Squibb drug known as Sprycel, to historical results from earlier trials of imatinib.

"More patients taking nilotinib or dasatinib are achieving complete responses more quickly than they do on either of two daily doses of imatinib," said Jorge Cortes, M.D., professor in M. D. Anderson's Leukemia Department and leader of both studies.

For example, 96 percent of those taking nilotinib and 94 percent of those on dasatinib reached a complete cytogenetic response at six months, compared with 54 percent of those taking 400 mg a day of imatinib and 85 percent of those taking 800 mg. Over the longer term up to 30 months, complete cytogenetic response induced by the two drugs is comparable to that of the higher-dose imatinib.

Complete cytogenetic response is the absence of the defective chromosome that causes the disease.

CML is caused by an abnormality known as the Philadelphia chromosome that produces an aberrant protein, Bcr-Abl, which causes the overproduction of one type of white blood cell that drives the disease. All three drugs are tyrosine kinase inhibitors, which block the action of Bcr-Abl. Nilotinib and dasatinib target more variations of the protein and often work after imatinib has failed. Both are approved by the U.S. Food and Drug Administration for patients who can't tolerate imatinib or whose CML resists the drug.

The dasatinib trial has enrolled 62 patients with previously untreated early stage CML taking either 50 mg twice daily or 100 mg once a day. Among 50 patients followed for at least three months, 49 (98 percent) achieved complete cytogenetic response. Major molecular response, a more stringent measure of remission, was reached in 35 patients (70 percent) with five (10 percent) achieving complete molecular response.

The researchers have dropped the twice daily arm of the trial, keeping the 100 mg once a day arm open because it has produced higher rates of major molecular response with fewer side effects.

The nilotinib trial has enrolled 65 patients with the 400mg twice daily dose producing complete cytogenetic responses in 50 of 51 patients (98 percent) followed for at least three months. Major molecular response has been achieved in 32 patients (63 percent) with 12 (24 percent) achieving complete molecular response.

All patients in both trials are alive, and enrollment continues. Side effects are being closely monitored and some patients in each trial had their treatment reduced or temporarily interrupted because of toxicities. Side effects are manageable and similar to those seen for imatinib, Cortes said.

Early results for both comparisons

Months on therapy Percent of patients with Complete Cytogenetic Response
Dasatinib Imatinib 400mg Imatinib 800mg
3 82 37 63
6 94 54 85
12 98 65 89
18 89 67 89
24 84 67 88
30 83 67 89

Months on therapy Percent of patients with Complete Cytogenetic Response (Number of valuable patients)
Nilotinib Imatinib 400mg Imatinib 800mg
3 90 37 63
6 96 54 85
12 97 65 89
18 93 67 89
24 93 67 88
30 92 67 89


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. AHF/India Cares Provides Second-line AIDS Drugs to Activists in India
2. Activist Groups Plea to Indian Prime Minister: Rollout Second-Line AIDS Treatment!
3. Simvastatin Leads Pfizers Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
4. More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro
5. Seroquels First- and Second-Line Patient Share Has Grown Since Last Years Analysis of Prescribing Trends in Bipolar Disorder
6. AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
7. New review suggests caution on drugs to raise good cholesterol
8. Can cancer drugs combine forces?
9. Study provides hope that some transplant patients could live free of antirejection drugs
10. Study provides hope that some transplant patients could live free of anti-rejection drugs
11. RA Drugs Linked to Slight Skin Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology: